Calyxo, Inc. — SEC Form D Filing
Calyxo, Inc. filed an SEC Form D on April 16, 2026, reporting $40.10M raised in Health Care.
Form D filing details
- Filing
- SEC Form D
- Filing date
- April 16, 2026
- Amount reported
- $40.10M
- Round stage
- Seed
- Industry
- Health Care
- Website
- https://calyxoinc.com/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Calyxo addresses the challenges of kidney stone treatment effectiveness and recovery time. Current methods can be invasive and less effective.
Solution
Calyxo provides the CVAC System, which enables the SURE Procedure, a minimally invasive method that improves stone clearance rates and patient outcomes.
Why now
With increasing rates of kidney stones and demand for effective treatments, there is a pressing need for advanced solutions in this area.
Verdict
Investors said yes primarily because the urgency surrounding kidney stone treatment and Calyxo's promise of improved outcomes resonated strongly at the time. They were implicitly betting on the increasing prevalence of kidney stones necessitating innovative solutions, not on a well-defined budget owner or a clear articulation of cost replacement. The limited upside lies in over-reliance on a niche market and insufficient differentiation from established players, which could lead to stagnation rather than sustainable growth.
Source: SEC EDGAR Form D filing